Fierce Biotech April 3, 2024
Asensus Surgical is weighing an offer to be acquired by Karl Storz following “an extensive period” of evaluating strategic alternatives for the future of the laparoscopic robot maker.
The German medtech staked its claim for Asensus with a deal to buy out all its shares at 35 cents apiece, representing a 66.7% premium over its recent trading price of 23 cents for a total in the ballpark of $95 million. Asensus’ stock jumped more than 30% on the news to about 30 cents per share, putting the company’s market cap just above $76 million.
But the ink is far from dry. So far, the two have only entered into a nonbinding letter of intent to give Karl Storz up to...
Today's Sponsors
Today's Sponsor